Brief: Bioton Says Biomm Terminates Deal For Commercialization Of Recombinant Human Insulin In Brazil

Bioton SA

09/09/2019 09:03

Sept 9 (Reuters) - Bioton SA  BIOP.WA :
   
    * SAID ON SATURDAY THAT IT HAS RECEIVED FROM BRAZIL-BASED
BIOMM A
DECLARATION OF THE TERMINATION OF DEAL FOR THE COMMERCIALIZATION
OF RECOMBINANT HUMAN INSULIN IN THE TERRITORY OF BRAZIL 
    * THE MAIN REASON FOR TERMINATION INDICATED BY BIOMM WAS THE
FAILURE TO SIGN THE AGREEMENT BETWEEN BIOMM AND THE MINISTRY OF
HEALTH OF BRAZIL REGARDING THE SUPPLY INSULIN TO BRAZIL 
    * IN ADDITION, THE AGREEMENT BETWEEN BIOMM AND THE MINISTRY
OF
HEALTH OF BRAZIL WAS TEMPORARILY SUSPENDED IN AUGUST BY THE
NATIONAL HEALTH SURVEILLANCE AGENCY - ANVISA
    * ALSO, PRODUCT REGISTRATION AT THE BRAZILIAN NATIONAL
HEALTH
SURVEILLANCE AGENCY HAS NOT BEEN GRANTED
    * BIOTON SAYS IT WILL ANALYZE THE LEGAL ISSUES OF
TERMINATION IN
ORDER TO CONDUCT THE FURTHER STEPS
    * BIOTON SAYS IT IS COMPLETING CLINICAL TRIALS AND
REGARDLESS OF
BIOMM'S DECISION, IT WILL CONTINUE TO REGISTER ON THE BRAZILIAN
MARKET



    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM5nfkJMa
    
 Further company coverage:  BIOP.WA